Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report 2026

The prostate-specific membrane antigen (psma) theranostic kits market size has grown rapidly in recent years. It will grow from $1.05 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to rising incidence of prostate cancer, advancements in nuclear medicine imaging, increasing adoption of molecular diagnostics, early clinical validation of psma targeting, expansion of oncology research programs.

The prostate-specific membrane antigen (psma) theranostic kits market size is expected to see rapid growth in the next few years. It will grow to $1.99 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to increasing demand for personalized cancer treatments, rising investments in theranostics, expansion of nuclear medicine infrastructure, growing use of precision oncology diagnostics, increasing regulatory approvals for targeted therapies. Major trends in the forecast period include increasing adoption of targeted radioligand therapies, rising use of psma-based precision diagnostics, growing integration of imaging and therapy workflows, expansion of personalized oncology treatment kits, enhanced focus on companion diagnostics.

The rising incidence of prostate cancer is expected to drive the growth of the prostate-specific membrane antigen (PSMA) theranostic kits market in the coming years. Prostate cancer is a type of cancer that develops in the prostate gland, a small gland in men located below the bladder and in front of the rectum. The increasing prevalence of prostate cancer is largely due to the aging population, as the risk of developing the disease rises significantly with age. PSMA theranostic kits support prostate cancer management by offering targeted diagnostic solutions, making them ideal for early detection and personalized treatment planning. They enhance diagnostic accuracy by combining PSMA-specific ligands with radiotracers, enabling better disease monitoring and therapy guidance. For example, in November 2023, the American Cancer Society estimated approximately 313,780 new cases of prostate cancer and 35,770 deaths in the United States in 2025. Therefore, the growing incidence of prostate cancer is propelling the PSMA theranostic kits market.

Major companies in the PSMA theranostic kits market are developing innovative solutions, such as PSMA-targeted radioligand kits, to meet the increasing demand for precision oncology, targeted prostate cancer diagnosis, and therapy. PSMA-targeted radioligand kits combine a ligand specifically designed to bind to PSMA with a radioactive isotope for diagnostic imaging or targeted treatment of prostate cancer. For instance, in March 2025, Telix Pharmaceuticals Limited, an Australia-based radiopharmaceutical company, launched Illuccix, a kit for the preparation of Gallium-68 gozetotide injection. This kit allows hospitals and nuclear medicine facilities to label the radionuclide immediately before injection for PET imaging of PSMA-positive prostate cancer lesions. Its features include a ready-to-use preparation format, disease-specific targeting, rapid imaging capability, and compatibility with theranostic workflows, enabling improved detection of metastatic lesions, personalized treatment planning, and therapy monitoring. The kit is applied in diagnosing recurrent or metastatic prostate cancer and guiding individualized treatment decisions, representing a significant advancement over conventional imaging or non-targeted therapies.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based biotech company, acquired Theragnostics Ltd. for an undisclosed amount. Through this acquisition, Ariceum Therapeutics aims to strengthen its capabilities in PSMA-targeted theranostic kits and expand its radiopharmaceutical portfolio for prostate cancer imaging. Theragnostics Ltd., based in the UK, develops PSMA-targeted diagnostic kits, specifically 68Ga THP PSMA, for prostate cancer imaging.

Major companies operating in the prostate-specific membrane antigen (psma) theranostic kits market are Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, AdvanCell Pty Ltd, Alpha‑9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, RadioMedix Inc., Scintomics GmbH, Novartis AG, Bayer AG, POINT Biopharma Inc., Blue Earth Diagnostics.

North America was the largest region in the prostate-specific membrane antigen (PSMA) theranostic kits market in 2025. The regions covered in the prostate-specific membrane antigen (psma) theranostic kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prostate-specific membrane antigen (psma) theranostic kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the PSMA theranostic kits market by increasing costs of imported radioisotopes, imaging agents, specialized synthesis equipment, and shielding materials used in diagnostic and therapeutic kits. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on cross-border nuclear medicine supply chains, while Asia-Pacific faces higher costs for advanced radiopharmaceutical components. These tariffs are increasing treatment costs and affecting kit availability timelines. However, they are also supporting domestic radiopharmaceutical manufacturing, regional isotope production initiatives, and localized supply chain development for theranostic solutions.

The prostate-specific membrane antigen (psma) theranostic kits market research report is one of a series of new reports that provides prostate-specific membrane antigen (psma) theranostic kits market statistics, including prostate-specific membrane antigen (psma) theranostic kits industry global market size, regional shares, competitors with a prostate-specific membrane antigen (psma) theranostic kits market share, detailed prostate-specific membrane antigen (psma) theranostic kits market segments, market trends and opportunities, and any further data you may need to thrive in the prostate-specific membrane antigen (psma) theranostic kits industry. This prostate-specific membrane antigen (psma) theranostic kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prostate-specific membrane antigen (PSMA) theranostic kits are specialized tools designed for the detection and treatment of prostate cancer by targeting the PSMA protein, which is highly expressed on cancer cells. They integrate a PSMA-targeted imaging agent for precise tumor localization with a therapeutic component that delivers treatment directly to cancer cells. These kits support personalized medicine by enhancing cancer staging, monitoring treatment response, and reducing damage to healthy tissues.

The main product types of PSMA theranostic kits include diagnostic kits, therapeutic kits, and combined theranostic kits. Diagnostic kits are used to detect and visualize PSMA-expressing cancer cells through imaging agents, allowing for accurate tumor localization, staging, and monitoring of prostate cancer. Their applications include prostate cancer management and related uses, serving end users such as hospitals, diagnostic centers, research institutes, specialty clinics, and others.

The prostate-specific membrane antigen (PSMA) theranostic kits market consists of sales of radiolabeled therapeutic agents, diagnostic kits, combination theranostic kits, antibody-based PSMA theranostics, PSMA ligand-based drug conjugates, and companion diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.